Graphical abstract Suspected clinical impacts of GLP-1RAs, SGLT2is, and finerenone oncardiovascular and kidney outcomes
This study population was divided into two cohorts: (1) semaglutide cohort 25,686 patients prescribed semaglutide, and (2) Non-GLP-1RA anti-diabetes medication cohort 573,117 patients prescribed non-GLP-1RA anti-diabetes medications
Systemic GLP-1 receptor deficiency impairs GLP-1-induced anorexia as anticipated.41 However, these mice do not display alterations in baseline body weight, suggesting that GLP-1 receptor is not critical for body weight regulation under basal conditions.41 Notably, subsequent investigations revealed that both male and female mice lacking systemic GLP-1 receptor are resistant to diet-induced obesity.39,42 Focusing on central mechanisms, intracerebroventricular administration of GLP-1 failed to modulate feeding behavior in GLP-1 receptor global knockout mice.41 Central inhibition of GLP-1 receptor disrupts glucose homeostasis and reduces food intake, whereas peripheral GLP-1 receptor inactivation impairs glucose-stimulated insulin secretion, diminishes glucose clearance, elevates glucagon levels, and accelerates gastric emptying
10.1016/j.biocontrol.2011.11.002 103 MaleckK.LevineA.EulgemT.MorganA.SchmidJ.LawtonK
The right choice depends on individual health history and goals, which is worth discussing with a healthcare provider
Therefore, repeated or omitted reporting is inevitable, which will affect the results of data mining
